Biocon and Viatris receive EC approval for Biosimilar Bevacizumab
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
The findings come from the first and only decentralized real-world study examining how HD chorea affects patients and caregivers and how treatment impacts quality of life
Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
About 250+ women riders participate in the awareness ride where free breast screening camp were conducted
Subscribe To Our Newsletter & Stay Updated